BioCentury
ARTICLE | Clinical News

Genesis, SR Pharma start Phase II eczema trial

September 10, 2003 7:00 AM UTC

Genesis Research (ASE:GEN) and SR Pharma (LSE:SPA) started a placebo-controlled New Zealand Phase II trial of AVAC to treat pediatric atopic dermatitis in 120 children ages 5-16. The primary endpoint ...